Specifications Table {#s0005}
====================

TableSubject areaMedical sciencesMore specific subject areaCardiac magnetic resonance spectroscopy and signaling pathwaysType of dataFigureHow data was acquiredMagnetic resonance spectroscopy, hypoxia and low flow ischaemia using isolated whole Langendorff-perfused mouse heartsData formatAnalyzedExperimental factorsMale mice were used.Experimental featuresThe effects of dystrophin deficiency on uncoupling protein-3 levels, glycogen levels, phosphocreatine and ATP concentrations throughout hypoxia, glucose uptake rates during low flow ischemia and insulin stimulation using D-\[2--^3^H\] glucose in *mdx* mouse hearts were determined.Data source locationUniversity of Oxford, United KingdomData accessibilityAll data are available with this article.

Value of the data {#s0010}
=================

•This data can be used to further investigate the role of dystrophin in obesity and elevated serum free fatty acids levels in human Duchenne muscular dystrophy patients.•The data can be used to determine whether decreased phosphocreatine and ATP concentrations cause decreased contractile functions after hypoxia or vice verse in *mdx* mouse hearts.•Glucose uptake rates and phospho-Akt data can be used to investigate the role of dystrophin in signaling.

1. Data {#s0015}
=======

*Mdx* mice have abnormal body weights, plasma free fatty acids concentrations and cardiac uncoupling protein-3 protein levels compared with wild-type mice. *Mdx* mouse hearts have decreased left ventricular contractile functions and faster ATP loss rates during hypoxia compared with wild-types. *Mdx* mouse hearts also have higher left ventricular end-diastolic pressures and lower glucose uptake rates during low flow ischemia than wild-types. Insulin-stimulated phospho-Akt protein levels are similar in all mouse hearts while *mdx* mouse hearts have lower glucose uptake rates in response to insulin than wild-types.

2. Experimental design, materials, and methods {#s0020}
==============================================

Experiments were carried out using male wild-type (C57BL10) (*n* = 61) and age-matched *mdx* (*n* = 62) mice at 8 months. All the procedures were approved by the Animal Ethics Review Committees, University of Oxford, and by the Home Office, United Kingdom. Plasma free fatty acids concentrations were measured using NEFA kit (Wako Chemicals). Western blot quantified protein levels with anti-uncoupling protein-3, anti-phospho-Akt (Cell Signaling) and anti-GAPDH (Abcam). Isolated whole Langendorff-perfused mouse hearts were equilibrated with fatty acids free Krebs-Henseleit buffer gassed with 95% O~2~ -- 5% CO~2~ (PaO~2~ = \~ 90 mmHg), and subjected to hypoxia with buffer gassed with 95% N~2~ -- 5% CO~2~ (PaO~2~ = \~ 45 mmHg) and reoxygenation. Left ventricular pressures and coronary flow were recorded. Protocols were shown in [Fig. 1](#f0005){ref-type="fig"}. Glycogen levels before ischemia or hypoxia were determined [@bib1]. Glucose uptake rates were calculated using D-\[2--^3^H\] glucose during low flow ischemia (0.5 ml min^−1^ gww^−1^) and in response to insulin [@bib2]. Statistical significance was assessed using one-way analysis of variance followed by Student׳s *t*-test.Fig. 1Body weights, plasma free fatty acids, western blot, hypoxia, low flow ischemia, and glycogen data. A: Body weights (*n* = 28 for wild-type, *n* = 30 for *mdx*); B: Plasma free fatty acids concentrations (*n* = 4 for wild-type, *n* = 5 for *mdx*); C: Uncoupling protein-3 (UCP3) western blot (*n* = 5 for wild-type, *n* = 5 for *mdx*); D--F, H: Hypoxia with glucose (*n* = 10 for wild-type; *n* = 12 for *mdx*); I--K, M: Hypoxia with pyruvate and lactate (*n* = 4 for wild-type; *n* = 5 for *mdx*); N, O: Phosphocreatine and ATP concentrations throughout hypoxia (*n* = 4 for wild-type, *n* = 5 for *mdx*). Q, R: Low flow ischemia with glucose (*n* = 10 for wild-type; *n* = 9 for *mdx*); S: Glucose uptake rates during low flow ischemia (*n* = 6 for wild-type; *n* = 5 for *mdx*); T, U: Low flow ischemia with pyruvate and lactate (*n* = 4 for wild-type; *n* = 5 for *mdx*); V: Cardiac glycogen levels (*n* = 6 for wild-type and *n* = 5 for *mdx* in both perfusions); W, X: Insulin-stimulated glucose uptake rates and phospho-Akt western blot (*n* = 5 for wild-type without and with insulin; *n* = 6 for *mdx* without and with insulin). LV RPP, left ventricular rate-pressure product; EDP, end-diastolic pressure; MRS, magnetic resonance spectroscopy. Substrate G: 11 mM glucose; GPL: 11 mM glucose, 1.8 mM pyruvate and 0.2 mM lactate; PL: 1.8 mM pyruvate and 0.2 mM lactate. Data are expressed as means ± SEM. \* *P* \< 0.05 vs. wild-type; † *P* \< 0.01 vs. wild-type; ‡ *P* \< 0.001 vs. non-insulin-stimulated wild-type; § *P* \< 0.001 vs. non-insulin-stimulated *mdx*; ǁ *P* \< 0.05 vs. insulin-stimulated wild-type.Fig. 1
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